RxDoctor Payments Data

Victorino Dejesus, MD

Internal Medicine · Georgetown, DENPI 1699713032

Payments from drug & device makers

$491in general payments, 2019–2025

Across 21 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$95
  • Abbott$67
  • Sanofi-aventis U.S. LLC$60
  • GSK$45
  • AstraZeneca$41
  • Boehringer Ingelheim$28
  • plus $155 from 9 others

What the payments were for

  • Speaking & faculty fees$7515%
  • Food & beverage$40482%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$491 in reported general payments places this provider in the 70th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$300,186
Medicare patients
562
Services billed
2,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide221$324,385
JardianceEmpagliflozin231$242,210
EliquisApixaban119$130,423
FarxigaDapagliflozin Propanediol109$108,977
MounjaroTirzepatide60$82,117
TrulicityDulaglutide42$63,203
JanuviaSitagliptin Phosphate34$43,443
XareltoRivaroxaban32$34,777
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$30,819
MyrbetriqMirabegron32$27,547
EntrestoSacubitril/Valsartan19$26,273
Breo ElliptaFluticasone/Vilanterol47$24,540
VascepaIcosapent Ethyl29$22,861
RybelsusSemaglutide11$20,270
Spiriva RespimatTiotropium Bromide21$15,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$16$344,655232 claims
Boehringer IngelheimJardiance, Spiriva Respimat$28$257,531252 claims
Lilly USA, LLCMounjaro, Trulicity$12$145,319102 claims
PfizerEliquis$12$130,423119 claims
AstraZenecaFarxiga$41$108,977109 claims
GSKTrelegy Ellipta, Breo Ellipta$45$55,35990 claims
AbbVieSavella, Linzess, Synthroid$21$36,340125 claims
Johnson & JohnsonXarelto$28$34,77732 claims
NovartisEntresto$12$26,27319 claims
Kowa Pharmaceuticals America, Inc.Livalo$18$13,27415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Georgetown

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →